GZBL(SZ:002424)2022-11-21 15:50Group 1: Investor Relations Activities - The investor relations activity was conducted with specific target research and included various participants from different investment firms [1] - The meeting took place on November 4, 2021, in Shanghai, with key company representatives presenting [2] Group 2: Marketing Network and Sales Strategy - The company has established a marketing network covering over 3,200 first and second-level hospitals across 32 provinces, cities, and autonomous regions [2] - The company has built business relationships with over 80% of terminal customers nationwide, totaling more than 470,000 terminal customers, including 85,000 VIP customers [3] - The marketing team is recognized as a core advantage, contributing to continuous sales growth [2][3] Group 3: Product Development and Research - The company has 17 exclusive苗药 (Miao medicine) products, making it a leader in the industry with the widest market coverage [3] - The company is actively promoting the糖宁通络 (Tang Ning Tong Luo) product through clinical research and partnerships with various medical institutions [4][5] - A national-level research project on糖宁通络 for diabetes treatment has been approved, involving multiple hospitals and experts [5] Group 4: Cost Management and Production Capacity - The company is implementing measures to control raw material costs through centralized procurement and improved production planning [4] - An expansion project initiated in 2020 is expected to increase the company's pre-extraction capacity by 35,000 tons per year, reaching a total capacity of 60,000 tons annually [5][6] - Continuous improvements in production lines and the introduction of advanced automated systems are being pursued to enhance production efficiency [6]